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Outcomes of Infants with
Nonimmune Hydrops Fetalis Born after
22 Weeks’ Gestation — Our Experience
between 1982 and 2000
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Background: The prognoses of the majority of infants with nonimmune hydrops
fetalis (NIHF) remain poor. We retrospectively investigated our previous cases of
NIHF to obtain perspectives for treatment of future NIHF.
Materials and Methods: The medical records of 101 cases of mothers and NIHF
infants delivered after 22 weeks’ gestation in our center between 1982 and 2000
were investigated.
Results: The overall perinatal mortality of NIHF was 65.9%. There were 16
intrauterine fetal deaths and 49 early neonatal deaths (within 28 days after delivery)
among the 101 cases. The poor mortality rate was attributed to structural anomaly
(mortality, 66.7%), congenital structural heart disease without arrhythmia (mortality,
86.7%), twin-to-twin transfusion syndrome (mortality, 80.0%) and cystic hygroma
(mortality, 91.9%). There were significant differences between survival and early
neonatal death for gestational age at referral, gestational age at delivery, birth weight,
and Apgar scores at 1 and 5 minutes (p < 0.05). As the number of extravascular
compartments with fluid accumulation increased, the neonatal prognosis became
poorer.
Conclusion: The outcome of NIHF correlated with the causal diseases. Earlier
intrauterine intervention than occurred among the women and fetuses in this study
may facilitate better prognoses for NIHF.
(J Med Ultrasound 2002;10:80–85)
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INTRODUCTION
Hydrops fetalis is a state of excessive fluid accu-
mulation in the extravascular compartments of the
fetus. The causes of hydrops fetalis can be largely
divided into two categories: immune causes and non-
immune causes. The most common immunity-related
cause is pregnancy complicated by maternal–fetal
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Rhesus (Rh)-negative incompatibility. Because the
percentage of Japanese with Rhesus-negative red blood
cells is small, and administration of anti-Rh anti-
body to the anti-Rh negative mother is widely
performed, hydrops fetalis due to immune causes is
rare in Japan. Thus, the majority of hydrops fetalis
in Japan is due to nonimmune causes.
Despite efforts to diagnose and treat nonimmune
hydrops fetalis (NIHF), it is difficult to predict the
prognosis, which is associated with high fetal and
neonatal mortality. When managing a pregnancy
complicated with NIHF, a treatment plan based on
the underlying disease should be prepared based on
diagnosing the cause of NIHF in detail. We re-
viewed the NIHF cases encountered in our hospital
and investigated the prognostic factors in these cases
to obtain future perspectives for the treatment of
NIHF.
MATERIALS AND METHODS
Between 1982 and 2000, 153 pregnant women whose
fetuses demonstrated excessive fluid accumulation
in one or more of the extravascular compartments
were treated in our hospital and their medical records
were reviewed and analyzed. All but one patient,
who was monitored from the beginning of her
pregnancy because of maternal congenital heart
disease (endocardial cushion defect), were referred
from other hospitals because of abnormal findings
on ultrasonography. We limited our investigation to
patients fulfilling the following criteria: 1) the NIHF
neonate was delivered after 22 weeks’ gestation;
2) isoimmunity-related NIHF was ruled out; and
3) excessive fluids were demonstrated in two or
more fetal body cavities, such as subcutaneous edema,
pleural effusion, ascites and pericardial effusion. We
regarded a cystic hygroma as one of the extravas-
cular fetal compartments. Fluid accumulations were
demonstrated on ultrasonography. Maternal–fetal and
neonatal medical records were reviewed to inves-
tigate the clinical course of NIHF. We obtained
informed consent from each patient for the diagnos-
tic methods and treatment. The local ethics commit-
tee also approved all methods used for diagnosis and
treatment.
In the diagnosis and treatment of NIHF in utero,
we took the following steps:
1. We closely evaluated the intrauterine fetal con-
dition by B-mode ultrasonography, Doppler study
and fetal heart rate monitoring (non-stress test).
2. We examined the fetus for chromosomal ab-
normalities using fetal blood or amniotic fluid
sampling when the patient consented.
3. For NIHF with pleural effusion, ascites or other
fluid accumulations, we tried to aspirate the pooled
fluids. We checked for viral or other infections
using viral polymerase chain reaction (PCR) and
bacterial culture methods.
4. We checked for fetal anemia and low blood
protein by cord blood sampling, and, if present,
considered fetal blood transfusion or protein
infusion.
5. The mode and gestational week for delivery in
NIHF patients were selected based on obstetric
indications.
We classified our study population into eight
categories according to cause as follows: 1) viral
infection; 2) structural anomaly other than heart
disease; 3) congenital structural heart disease (CHD);
4) arrhythmia without CHD; 5) placental
hemangioma, 6) twin-to-twin transfusion syndrome
(TTTS); 7) cystic hygroma; and 8) idiopathic hydrops.
The criteria were modified from causal classifica-
tions of NIHF [1]. The outcomes of our patients
were analyzed based on our causal classification. In
this analysis, neonates that survived for more than
28 days after delivery were defined as “surviving”.
Mortality before 28 days after delivery was defined
as “death”. Results are expressed as mean ± standard
deviation when appropriate.
Significance of differences was verified using
Student’s t-test. Results were considered statistically
significant when p < 0.05.
RESULTS
Among the 153 pregnant women who were referred
for fetuses with fluid accumulation in the fetal
extravascular spaces, 101 fulfilled our criteria for
fetuses with NIHF. The mean gestational week at
referral was 29.1 ± 4.4 and 49.5% of the mothers
were primipara. B scan at the first referral demon-
strated pleural effusion in 81 cases (80.2%), ascites
in 84 cases (83.2%), subcutaneous edema in 87
cases (86.1%) and pericardial effusion in 21 cases
(20.8%). Cystic hygroma was demonstrated in 11
cases.
Table 1 shows the outcomes of NIHF based on
our causal classifications. There were 85 liveborn
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infants and 16 intrauterine fetal deaths (IUFDs).
Fifty-four fetuses (including seven IUFDs) were
male and 47 (including nine IUFDs) were female.
Birth by cesarean section accounted for 68.3% of
births. The most frequent reason for cesarean section
was discouraging findings on fetal heart rate
monitoring.
Consent for chromosomal analysis was obtained
in 63 cases. Abnormal chromosomes were identified
in 11 cases; six cases of 47XY,+21; three cases of
47XX, +21; one case of 47XY, +18; one case of
46 XY inv(9). There was no correlation between
chromosomal anomaly and fetal outcome.
Viral cultures were positive in three cases. Two
fetuses, one born live and one stillborn, were in-
fected with parvo B-19 virus, and the other case
involved cytomegalovirus infection.
Therapeutic interventions were performed in 67
of 101 cases. The most common intervention was
therapeutic aspiration of accumulated fluids in (46/
67 cases). Nonetheless, 25 of the 46 cases ended
in IUFD or early neonatal death. Transplacental fetal
therapy, mainly maternal oral administration of
digoxin, was performed in 14 of 67 cases. Direct
fetal infusion of blood and albumin were performed
in four and seven cases, respectively.
Total neonatal mortality, the rate of early neonatal
death among all live births, was 56.5% (Table 1).
Poor neonatal mortality based on our causal clas-
sification was noted in CHD, TTTS and cystic
hygroma. There were only four surviving neonates
with CHD; two had double outlet of the right
ventricle, one had Ebstein anomaly and one had a
common atrioventricular canal. Six of 11 infants
with cystic hygroma died in utero and four of the
five liveborn infants died in the early neonatal period.
Only one infant with a single cyst of hygroma
survived following intrauterine aspiration of the
intracystic fluid. Four of the fetuses with TTTS were
born soon after the intrauterine death of one of the
twins, but all ended in early neonatal death. In one
case of TTTS with liveborn twins, one of the neonates
died in the early neonatal period, but the other twin
survived.
Table 2 shows the obstetric data of NIHF infants
who were born alive. All data such as gestational
week at referral, birth gestational week, birth weight,
and Apgar scores at 1 and 5 minutes were significantly
Table 1. Mortalities of nonimmune hydrops fetalis (NIHF) based on causal classification
Causes of NIHF n Intrauterine Early neonatal Total
mortality (%) mortality (%) mortality (%)
Viral infection 3 33.3 0.0 33.3
Structural anomaly* 3 0.0 66.7 66.7
CHD 30 16.7 84.0 86.7
Arrhythmia† 11 9.1 30.0 36.4
Placental hemangioma 2 0.0 0.0 0.0
TTTS 5 0.0 80.0 80.0
Cystic hygroma 11 54.5 36.4 90.9
Idiopathic hydrops 36 8.3 42.4 50.0
Total 101 15.8 56.5 63.4
*Structural anomaly except heart disease; †Arrhythmia without CHD. CHD = congenital structural heart disease; TTTS = twin-
to-twin transfusion syndrome.
Table 2. Perinatal characteristics of liveborn nonimmune hydrops fetalis infants
n Referral Birth Birth Apgar Apgar
GW GW weight (g) at 1 min at 5 min
Survived* 36 31.2 ± 3.6 34.3 ± 2.7 2,562 ± 669 4.3 ± 2.6 6.8 ± 2.2
Died† 49 28.6 ± 4.1 32.0 ± 3.5 2,040 ± 646 2.3 ± 2.1 3.2 ± 2.4
Total 85 29.7 ± 4.1 33.0 ± 3.4 2,261 ± 702 3.1 ± 2.5 4.7 ± 2.9
*Neonate lived longer than 28 days; †neonate died within 28 days after birth. GW = gestational week; Apgar = Apgar score.
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lower (p < 0.05) in infants with early neonatal deaths
than in surviving infants with NIHF.
Although early neonatal survival was not influ-
enced by the existence of pleural effusion (Table
3), the number of extravascular spaces with fluid
accumulation correlated with poor fetal outcome
(Table 4).
The Figure shows the changes in survival rate
(the ratio of surviving NIHF to all liveborn NIHF)
with advances in gestational week for CHD, fetal
arrhythmia without CHD, and idiopathic NIHF. The
survival rates for all three causes were low until 32
weeks’ gestation. Note that the survival rate of CHD
remained low even after 32 weeks’ gestation, while
the survival rates for cases of fetal arrhythmia and
idiopathic NIHF increased after 32 weeks’ gestation.
DISCUSSION
The overall mortality for NIHF in our study was
63.4% (36 survivals among 101 fetuses). Reported
fetal and neonatal mortality due to NIHF ranges
from 50% to 100% [2–6], similar to the results of
our study. NIHF resulted in the deaths of 65 infants,
including 16 stillbirths. For the fetuses with parvo
B-19 virus infection, severe anemia was confirmed
by cordocentesis and ended in intrauterine fetal
death, although fetal red cell transfusion had been
planned. The other 15 stillbirths were not anti-
cipated.
When the incidence of NIHF was stratified by
cause, cardiovascular diseases were the most com-
mon (40.6%). A similar result was reported in a
series of 402 cases [7]. The incidence of idiopathic
NIHF has been reported to be 22% [5] and 19%
[8]. The rate of idiopathic causes in our study was
high compared to that in those reports, which might
be due to the fact that idiopathic causes in our study
included possible cases of congenital chylothorax.
The diagnosis of congenital chylothorax is made by
the presence of chylomicrons in the pleural fluid
after feeding. Although the lymphocyte cell count
in pleural fluid is used for intrauterine diagnosis of
chylothorax, it is reported that lymphocyte counts
in the pleural fluid alone are not sufficient to confirm
the diagnosis of fetal hydrothorax before birth, and
postnatal diagnosis of chylothorax is indispensable
[9]. Because pleural fluids disappeared before the
beginning of milk feeding in all of our cases, we
could not diagnose chylothorax.
The mortalities of NIHF with fetal TTTS and
with CHD are reported to be 100% and 91%, re-
spectively [10]. The poor survival of our fetuses
with NIHF due to these causes was similar.
Table 3. Early neonatal outcome of nonimmune hydrops fetalis (NIHF) with or without pleural effusion
NIHF mortality
With pleural effusion Without pleural effusion
Survived* 7 11
Died† 40 25
(χ2 = 2.944, p = 0.0862)
*Neonate lived longer than 28 days; †neonate died within 28 days after birth.
Table 4. Effect of number of compartments with fluid accumulation on early neonatal outcome of non-
immune hydrops fetalis
Number of compartments with fluid accumulation
Neonatal outcome 2 3 4
Survived* 18 12 1
Died† 14 24 9
(χ2 = 7.953, p = 0.0188)
*Neonate lived longer than 28 days; †neonate died within 28 days after birth.
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The presence of pleural effusion was reported to
carry a poor prognosis for NIHF because massive
pleural effusion in utero might be a cause of lung
hypoplasia [1]. However, there was no significant
difference in the mortality between fetuses with and
without pleural effusion in our study. Our aggressive
intrauterine treatments might be one cause of the
insignificant difference. Similarly, the survival rate
for NIHF cases in the intrauterine treatment group
was higher than that in the non-treatment group [11,
12]. However, contrary to these results, it is also
reported that there has not been an improvement in
the outcome of NIHF despite advances in maternal
and neonatal care [13]. The effectiveness of some
intrauterine treatments remains controversial.
Gestational weeks at NIHF diagnosis of surviv-
ing fetuses were later than those of fetuses and
neonates who died [12]. Early onsets of hydropic
conditions might indicate the severity of the under-
lying disease and early timing of delivery increased
the prematurity of the neonate. Birth weights of
surviving neonates were significantly higher than in
those who died. Apgar scores of surviving neonates
at 1 and 5 minutes were significantly higher than
in those who died. NIHF mortality increased as the
number of extravascular compartments with fluid
accumulation increased. These findings may indicate
that both the severity of NIHF and resuscitation at
birth influence the outcome of NIHF.
The prognoses of NIHF with fetal arrhythmia and
without CHD were better than in those with idio-
pathic NIHF. This may be due to the effectiveness
of intrauterine treatments such as transplacental
therapies for fetal arrhythmia [14] or therapeutic
aspiration of pleural effusion [11]. Nonetheless, the
outcomes of CHD were poor, as shown in the Figure,
despite efforts of transplacental therapy or aspiration.
Given the poor prognosis of NIHF despite therapy,
more aggressive intrauterine interventions performed
even earlier than those presently available may be
required. Challenging tasks such as intra-
uterine fetal heart surgery, lipopolysaccharide injec-
tions into cystic hygroma [15] and ablation of
communicating vessels in TTTS [16] may be pro-
spective treatments for NIHF with a poor prognosis.
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